Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -14.19% is 83% above its 5-year average of -82.66%, near the high end of its 5-year range (-150.21%–15.64%).
1.70% below its 12-month average of -13.95%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -16.88%.
EBITDA MARGIN
-14.19%
EBITDA MARGIN AVG TTM
-13.95%
EBITDA MARGIN AVG 3Y
-60.74%
EBITDA MARGIN AVG 5Y
-82.66%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.70%
CURRENT VS 3Y AVG
+76.64%
CURRENT VS 5Y AVG
+82.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Adaptive Biotechnologies Corporation
Market Cap
$4.78B
EBITDA Margin
-14.19%
TTM Avg
-13.95%
3Y Avg
-60.74%
5Y Avg
-82.66%
Market Cap
$4.92B
EBITDA Margin
-8718.32%
TTM Avg
-5172.73%
3Y Avg
-3124.55%
5Y Avg
-2649.58%
Market Cap
$5.02B
EBITDA Margin
9.15%
TTM Avg
-7.04%
3Y Avg
-33.99%
5Y Avg
-33.99%
Market Cap
$5.20B
EBITDA Margin
-395.82%
TTM Avg
-536.17%
3Y Avg
-471.62%
5Y Avg
-471.62%
Market Cap
$5.20B
EBITDA Margin
21.06%
TTM Avg
20.50%
3Y Avg
18.63%
5Y Avg
16.67%
Market Cap
$5.27B
EBITDA Margin
-1035.18%
TTM Avg
-586.23%
3Y Avg
-456.90%
5Y Avg
-388.23%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation (ADPT) | $4.78B | -14.19% | -13.95% | -60.74% | -82.66% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.81B | N/A | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.92B | -8718.32% | -5172.73% | -3124.55% | -2649.58% |
| BillionToOne, Inc. (BLLN)vs › | $5.02B | 9.15% | -7.04% | -33.99% | -33.99% |
| Erasca, Inc. (ERAS)vs › | $5.11B | N/A | N/A | N/A | N/A |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.20B | -395.82% | -536.17% | -471.62% | -471.62% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.20B | 21.06% | 20.50% | 18.63% | 16.67% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.34B | N/A | N/A | N/A | N/A |
| Cogent Biosciences, Inc. (COGT)vs › | $5.27B | -1035.18% | -586.23% | -456.90% | -388.23% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.21B | -250.61% | -502.94% | -374.26% | -228.13% |
Gross Margin
75.4%
EBITDA Margin
-14.2%
Operating Margin
-20.6%
Net Margin
-20.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -16.88% |
| 2026-03-31 | -21.68% |
| 2025-12-31 | -11.97% |
| 2025-09-30 | 15.64% |
| 2025-06-30 | -34.87% |
| 2025-03-31 | -50.44% |
| 2024-12-31 | -61.93% |
| 2024-09-30 | -60.39% |
| 2024-06-30 | -97.97% |
| 2024-03-31 | -104.00% |
| 2023-12-31 | -143.45% |
| 2023-09-30 | -119.18% |
| 2023-06-30 | -82.44% |
| 2023-03-31 | -137.51% |
| 2022-12-31 | -61.42% |
| 2022-09-30 | -83.73% |
| 2022-06-30 | -108.35% |
| 2022-03-31 | -150.21% |
| 2021-12-31 | -149.61% |
| 2021-09-30 | -133.78% |
| 2021-06-30 | -121.70% |
| 2021-03-31 | -100.43% |
| 2020-12-31 | -145.14% |
| 2020-09-30 | -132.72% |
| 2020-06-30 | -166.34% |
| 2020-03-31 | -156.11% |
| 2019-12-31 | -91.34% |
| 2019-09-30 | -61.36% |
| 2019-06-30 | -64.30% |
| 2019-03-31 | -144.18% |
| 2018-12-31 | -73.00% |
| 2018-09-30 | -44.78% |
| 2018-06-30 | -102.20% |
| 2018-03-31 | -120.30% |
